Registered title, quoted from ClinicalTrials.gov
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
An open trial on neuroblastoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07516678, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients with histologically or clinically confirmed neuroblastoma according to institutional or protocol-defined diagnostic criteria.
Newly diagnosed, relapsed, refractory, or progressive neuroblastoma eligible for serial biospecimen collection during routine clinical care.
Availability of peripheral blood samples for ctDNA/MRD analysis at baseline and/or longitudinal follow-up time points.
Availability of clinical data required for molecular-clinical correlation analyses, including response and outcome assessment.
Availability of tumor tissue and matched control samples for tumor-informed assay development, if applicable and feasible.
Written informed consent from a parent or legal guardian, and assent from the participant when applicable.
Exclusion Criteria:
- Inability to provide protocol-required blood samples for ctDNA/MRD testing. Insufficient clinical information for protocol-defined response or outcome analyses.
Poor-quality or insufficient biospecimens that preclude molecular analysis, when molecular testing is a required component of the study dataset.
Any condition that, in the opinion of the investigator, would make study participation inappropriate.
Quoted from ClinicalTrials.gov, NCT07516678, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07516678, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.